News|Articles|September 20, 2024
Reliable and Objective Antibody Analysis with the New Agilent ProteoAnalyzer System
Author(s)Agilent Technologies
This technical overview compares the characterization of NISTmAb using the ProteoAnalyzer with published NIST data obtained via traditional single capillary CE-SDS technology. The results show strong correlation with the reference data, confirming that the ProteoAnalyzer is a reliable tool for analytical workflows.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
Distribution Resilience: Meeting Global Demand and Delivering Faster, More Reliable Service
2
Top 10 Questions from CPHI Frankfurt: Building Pharma Resilience a Common Theme
3
Streamlining Procurement and Inventory Management Leads to Increased Productivity
4
2025 PharmSci 360 to Showcase Essential AI Integration and Emerging Technologies
5
